Associated Papers
Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers.
Lee HG et al.
Cancer Research and Treatment, 2026
39973140 (PubMed )
Supplement: crt-2024-947_S10_Table.pdf
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.
Ryan MB et al.
Cancer Discovery, 2024
38588399 (PubMed )
Supplement: cd-24-0139_supplementary_table_6_suppst6.xlsx › OMNI
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX et al.
Molecular Cancer Therapeutics, 2019
31439712 (PubMed )
Supplement: 15357163mct190170-sup-217436_2_supp_5691166_pvrtk4.xlsx › PTPN11_shRNA_data
Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer.
Carter R et al.
Cancer Biology & Medicine, 2019
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
Select a paper to view details